<DOC>
	<DOCNO>NCT01102595</DOCNO>
	<brief_summary>In last 20 year , temozolomide obtain indication treatment High-grade glioma ( HGG ) . Temozolomide later radiation therapy double one year survival standard treatment glioblastoma . But 30 % glioblastomas receive biopsy ca n't resect n't get benefit treatment . They treat immediately biopsy prevent neurological deterioration spite approach often deteriorate neurologically radiotherapy . . An effective pre-radiation treatment improve prognosis allow complete concomitant radiotherapy temozolomide treatment . Bevacizumab recurrent HGG display 63 % objective response combine irinotecan . But irinotecan active treatment disease . We propose phase II , two arm , open label , randomize , multicentric study 2 cycle temozolomide radiation therapy concomitant temozolomide , patient glioblastoma 'biopsy-only ' . Bevacizumab add one arm .</brief_summary>
	<brief_title>Neo-adjuvant Treatment With Temozolomide Bevacizumab Previous Temozolomide Plus Radiation Plus Bevacizumab Therapy Unresectable Glioblastoma</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>1 . Patients glioblastoma , nonresectable , biopsy . Accepting craniotomy resection attempt RMN within period 72 hour confirm resection le 25 % tumor fulfill criterion 2 . Measurable disease contrast uptake ≥ 3 cm one diameter . 3 . Stable dos dexamethasone week prior inclusion . 4 . Performance Status ≤ 2 . 5 . Age ≤ 75 year . 6 . MiniMental Status &gt; 25/30 . 7 . Bartel index &gt; 50 % . 8 . The surgical incision heal prior randomization . The treatment start 3 week simple stereotactic biopsy 4 week case open biopsy ( craniotomy ) . 9 . Maximum baseline MRI perform 4 week start treatment ( acceptance MRI do neuronavegation biopsy baseline ) . 10 . Adequate bone marrow reserve : neutrophil &gt; 2000x109/L , platelet &gt; 100x109/L , hemoglobin≥106g/dl . 11 . Not received prior treatment chemotherapy radiation . 12 . Adequate renal function : Creatinine &lt; 1.5 ULN laboratory perform analysis . 13 . Adequate liver function : Serum bilirubin &lt; 1.5/ULN SGOT , SGPT &lt; 2.5ULN . Serum alkaline phosphatase &lt; 3/ULN . 14 . Absence proteinuria . 15 . Effective method contraception patient partner . 16 . Written inform consent 17 . Collecting material double histological confirmation diagnosis . 1 . Prior radiotherapy chemotherapy treatment glioma . 2 . Less 5 year prior invasive neoplasia . Accepted carcinoma situ cervix carcinoma cutaneous vasocelular . 3 . Cerebral hemorrhage biopsy . 4 . Pregnancy lactation . 5 . Clinically significant cardiovascular disease : Myocardial infarction unstable angina ( ≤ 6 month randomization ) Congestive heart failure ( CHF ) class ≥ II NYHA , New York Heart Association . Cardiac Arrhythmia uncontrolled despite medication ( may include patient atrial fibrillation often control ) . Peripheral vascular disease ≥ grade 3 ( ie , symptomatic interfering everyday activity specify repair review ) . 6 . Continued use aspirin &gt; 325 mg / day , currently recently ( within 10 day prior randomization ) . 7 . Currently establish treatment therapeutic dos anticoagulant Coumarin derivative ( courmarina , warfarin ) week start treatment . It allow administration heparin control Deep Vein Thrombosis ( DVT ) 8 . Patients PTSD patient inflammatory bowel disease , risk perforation . 9 . HT value 150 mmHg systolic pressure 100 mmHg diastolic tension controllable standard antihypertensive drug . 10 . Not healed scar , ulcer recent bone fracture . 11 . Bleeding diathesis coagulopathy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Unresectable/inoperable glioblastoma</keyword>
</DOC>